FDA-Approved Small Molecules in 2022: Clinical Uses and Their Synthesis

Davide Benedetto Tiz; Luana Bagnoli; Ornelio Rosati; Francesca Marini; Claudio Santi; Luca Sancineto

doi:10.3390/pharmaceutics14112538

FDA-Approved Small Molecules in 2022: Clinical Uses and Their Synthesis

Pharmaceutics. 2022 Nov 21;14(11):2538. doi: 10.3390/pharmaceutics14112538.

Authors

Davide Benedetto Tiz¹, Luana Bagnoli¹, Ornelio Rosati¹, Francesca Marini¹, Claudio Santi¹, Luca Sancineto¹

Affiliation

¹ Group of Catalysis, Synthesis and Organic Green Chemistry, Department of Pharmaceutical Sciences, University of Perugia, Via del Liceo 1, 06123 Perugia, Italy.

Abstract

This review describes the recently FDA-approved drugs (in the year 2022). Many of these products contain active moieties that FDA had not previously approved, either as a single ingredient or as part of a combination. These products frequently provide important new therapies for patients with multiple unmet diseases. The diverse small molecules are described according to the date of approval and their syntheses is discussed. This review comprises classical chemical scaffolds together with innovative drugs such as a deuterium-containing drug.

Keywords: FDA; drugs; new therapies; synthesis.

Publication types

Review

Abstract

Publication types

Grants and funding